Loading clinical trials...
Loading clinical trials...
MAGNITUDE-2: A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NTLA-2001 in Participants With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN)
Conditions
Interventions
nexiguran ziclumeran
Normal Saline as Placebo
Locations
14
Argentina
Hospital Británico de Buenos Aires
Buenos Aires, Argentina
Hospital Italiano de Buenos Aires (HIBA)
Buenos Aires, Argentina
Hospital El Cruce
San Juan Bautista, Argentina
Hospital das Clinicas da Universidade Estadual de Campinas (UNICAMP)
Campinas, Brazil
HCFMRP - Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto
Ribeirão Preto, Brazil
Instituto de Educacao, Pesquisa e Gestao em Saude
Rio de Janeiro, Brazil
Start Date
November 22, 2024
Primary Completion Date
July 1, 2027
Completion Date
August 1, 2028
Last Updated
April 16, 2026
NCT06821230
NCT00271622
NCT05508789
NCT06084026
NCT07357428
NCT07021638
Lead Sponsor
Intellia Therapeutics
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions